Organization | Australia and New Zealand Breast Cancer Trials Group

Australia and New Zealand Breast Cancer Trials Group Report issue

Academic/Hospital Phase 2 Phase 3

Organization Overview

First Clinical Trial

2007

NCT00659373

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2007

Timeline

NOW

Now

Alternative names

Breast Cancer Trials, Australia and New Zealand

Active Ingredients

Drugs in Phase 3 Trials (3)

exemestane (aromasin) (1 trial)

tamoxifen (nolvadex) (1 trial)

triptorelin (Trelstar) (1 trial)

Drugs in Phase 2 Trials (4)

capecitabine (xeloda) (1 trial)

pembrolizumab (keytruda) (1 trial)

trastuzumab (herceptin) (1 trial)

tucatinib (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Breast Neoplasms (Phase 3)

Fatigue (Phase 3)

Parasomnias (Phase 3)

Sleep Wake Disorders (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 2
# of Trial APIs: 7